2023
TP53 Mutation-driven Stratified Mucin-producing Carcinoma Coexisting With Squamous Cell Carcinoma of the Vulva: A Case Study
Wadia R, McHenry A, Abi-Raad R, Hui P. TP53 Mutation-driven Stratified Mucin-producing Carcinoma Coexisting With Squamous Cell Carcinoma of the Vulva: A Case Study. International Journal Of Gynecological Pathology 2023, 42: 555-560. PMID: 37255422, DOI: 10.1097/pgp.0000000000000961.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaInvasive squamous cell carcinomaVulvar intraepithelial neoplasiaCell carcinomaIntraepithelial neoplasiaLichen sclerosusAssociated with high-risk human papillomavirus infectionHigh-risk human papillomavirus infectionDifferentiated vulvar intraepithelial neoplasiaPresence of lymphovascular invasionInguinal lymph node metastasisHuman papillomavirus infectionVulvar lichen sclerosusMucin-producing carcinomaLymph node metastasisIntraepithelial lesionsLymphovascular invasionTP53 mutationsNode metastasisPapillomavirus infectionNeoplastic componentsCarcinomaUnique caseTP53Sclerosus
2022
Intraductal papillary neoplasm of the bile duct: Cytomorphologic and molecular features
Stendahl K, Gilani SM, Basturk O, Hui P, Sigel C, Cai G. Intraductal papillary neoplasm of the bile duct: Cytomorphologic and molecular features. Cancer Cytopathology 2022, 131: 37-49. PMID: 36041224, PMCID: PMC9812877, DOI: 10.1002/cncy.22637.Peer-Reviewed Original ResearchConceptsIntraductal papillary neoplasmBile ductCytomorphologic featuresFine granular chromatinPapillary neoplasmVacuolated cytoplasmGranular chromatinCase of IPNBColumnar cellsComplex papillary architectureOriginal cytological diagnosisCommon bile ductCharacteristic cytomorphologic featuresHigh-grade dysplasiaMolecular featuresBackground mucinKRAS testingHepatic ductRetrospective studyAcute inflammationHistopathologic confirmationKRAS mutationsPapillary architecturePapillary clustersCytological diagnosis
2020
Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan
Zeybek B, Manzano A, Bianchi A, Bonazzoli E, Bellone S, Buza N, Hui P, Lopez S, Perrone E, Manara P, Zammataro L, Altwerger G, Han C, Tymon-Rosario J, Menderes G, Ratner E, Silasi DA, Huang GS, Azodi M, Schwartz PE, Santin A. Cervical carcinomas that overexpress human trophoblast cell-surface marker (Trop-2) are highly sensitive to the antibody-drug conjugate sacituzumab govitecan. Scientific Reports 2020, 10: 973. PMID: 31969666, PMCID: PMC6976591, DOI: 10.1038/s41598-020-58009-3.Peer-Reviewed Original ResearchConceptsSquamous cell carcinomaSacituzumab govitecanTrop-2 expressionAntibody-drug conjugatesCell surface markersXenograft modelTrop-2Adenocarcinoma/adenosquamous carcinomaAnti-Trop-2 antibodyCell linesWeekly intravenous administrationSignificant tumor growth inhibitionCervical cancer patientsPrimary cervical cancerStrong diffuse stainingPrimary cervical tumorsCervical cancer cell linesEpithelial solid tumorsReal-time polymerase chain reactionTumor growth inhibitionHuman placental tissuePositive cell linesNegative cell linesVivo antitumor activityCancer cell lines
2015
Diagnostic application of KRAS mutation testing in uterine microglandular proliferations
Hong W, Abi-Raad R, Alomari AK, Hui P, Buza N. Diagnostic application of KRAS mutation testing in uterine microglandular proliferations. Human Pathology 2015, 46: 1000-1005. PMID: 25997988, DOI: 10.1016/j.humpath.2015.03.010.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overBiopsyCell ProliferationCervix UteriDiagnosis, DifferentialDNA Mutational AnalysisEndometrial HyperplasiaEndometrial NeoplasmsFemaleHumansMiddle AgedMutationPredictive Value of TestsProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsConceptsKRAS mutation analysisEndometrial adenocarcinomaMicroglandular hyperplasiaMicroglandular patternKRAS mutationsCareful morphological assessmentEndometrial mucinous carcinomaKRAS mutation testingCases of EMAMutation analysisFrequent KRAS mutationsElectronic medical recordsDifferential diagnostic toolHigh mitotic activityEndometrial biopsyImmunohistochemical workupUterine cervixMucinous carcinomaClinical historyDiagnostic challengeDiagnostic dilemmaGlandular proliferationMucinous lesionsMedical recordsEAC cases
2013
Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instability
Much M, Buza N, Hui P. Tissue identity testing of cancer by short tandem repeat polymorphism: pitfalls of interpretation in the presence of microsatellite instability. Human Pathology 2013, 45: 549-555. PMID: 24444463, DOI: 10.1016/j.humpath.2013.10.022.Peer-Reviewed Original ResearchAdaptor Proteins, Signal TransducingAdenocarcinomaAdenosine TriphosphatasesAdultAgedAged, 80 and overAllelesColorectal NeoplasmsDNA Mismatch RepairDNA Repair EnzymesDNA-Binding ProteinsEndometrial NeoplasmsEsophageal NeoplasmsFemaleGenetic LociGenotypeHumansMaleMicrosatellite InstabilityMicrosatellite RepeatsMiddle AgedMismatch Repair Endonuclease PMS2MutL Protein Homolog 1MutS Homolog 2 ProteinNuclear ProteinsPolymorphism, GeneticMarked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma
Buza N, Hui P. Marked heterogeneity of HER2/NEU gene amplification in endometrial serous carcinoma. Genes Chromosomes And Cancer 2013, 52: 1178-1186. PMID: 24123408, DOI: 10.1002/gcc.22113.Peer-Reviewed Original ResearchConceptsEndometrial serous carcinomaHER2/neu gene amplificationNeu gene amplificationSerous carcinomaHER2 protein expressionGene amplificationHeterogeneous tumorsProtein expressionHER2 testing guidelinesHER2 protein overexpressionTumor tissue areaTumor tissue sectionsHER2 statusDifferent tumor samplesHER2 overexpressionHER2 amplificationBreast cancerImmunohistochemical scoreAggressive subclonesCarcinomaClinical testingImmunostaining patternTumor samplesTumor cellsTesting guidelinesScreening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing.
Liu Y, Wu BQ, Zhong HH, Hui P, Fang WG. Screening for EGFR and KRAS mutations in non-small cell lung carcinomas using DNA extraction by hydrothermal pressure coupled with PCR-based direct sequencing. International Journal Of Clinical And Experimental Pathology 2013, 6: 1880-9. PMID: 24040454, PMCID: PMC3759496.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdenocarcinoma of LungAdultAgedAged, 80 and overBiopsyCarcinoma, Non-Small-Cell LungCarcinoma, Squamous CellDNA Mutational AnalysisErbB ReceptorsExonsFemaleGene FrequencyGenetic Predisposition to DiseaseGenetic TestingHumansLung NeoplasmsMaleMiddle AgedMutationParaffin EmbeddingPhenotypePolymerase Chain ReactionPrecision MedicinePredictive Value of TestsPressurePrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsTissue FixationYoung AdultConceptsNon-small cell lung carcinomaCore needle biopsyCell lung carcinomaKRAS mutationsNSCLC patientsSurgical resectionEGFR mutationsLung carcinomaNeedle biopsyKRAS mutation analysisTyrosine kinase inhibitorsKRAS gene mutationsDirect sequencingMutation analysisFemale patientsAdenocarcinoma componentLung cancerPatientsEGFRExon 19Kinase inhibitorsExon 18Gene mutationsStatistical significanceResectionKRAS Mutations are Associated With Specific Morphologic Features in Colon Cancer
Gunal A, Hui P, Kilic S, Xu R, Jain D, Mitchell K, Robert M, Kenney B. KRAS Mutations are Associated With Specific Morphologic Features in Colon Cancer. Journal Of Clinical Gastroenterology 2013, 47: 509-514. PMID: 23090042, DOI: 10.1097/mcg.0b013e3182703030.Peer-Reviewed Original ResearchConceptsKRAS mutation statusKRAS mutationsSpecific morphologic featuresColon cancerMorphologic featuresMutation statusAnti-epidermal growth factor receptor therapyDNA mismatch repair gene mutationsPeritumoral lymphocytic responseT3-T4 statusStage IV diseaseMismatch repair gene mutationsColon cancer resectionTime of resectionRight-sided locationRepair gene mutationsPearson χ2 testAdenocarcinoma morphologyKRAS testingCancer resectionLymphovascular invasionHistologic featuresReceptor therapyLymphocytic responseHistologic characteristicsIdentification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma
Cai G, Wong R, Chhieng D, Levy GH, Gettinger SN, Herbst RS, Puchalski JT, Homer RJ, Hui P. Identification of EGFR mutation, KRAS mutation, and ALK gene rearrangement in cytological specimens of primary and metastatic lung adenocarcinoma. Cancer Cytopathology 2013, 121: 500-507. PMID: 23495083, DOI: 10.1002/cncy.21288.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAnaplastic Lymphoma KinaseBiomarkers, TumorBone NeoplasmsCytodiagnosisDNA, NeoplasmErbB ReceptorsFeasibility StudiesFemaleGene RearrangementHumansIn Situ Hybridization, FluorescenceLiver NeoplasmsLung NeoplasmsMaleMiddle AgedMutationNeoplasm Recurrence, LocalPrognosisProto-Oncogene ProteinsProto-Oncogene Proteins p21(ras)Ras ProteinsReal-Time Polymerase Chain ReactionReceptor Protein-Tyrosine KinasesSoft Tissue NeoplasmsYoung AdultConceptsALK gene rearrangementMetastatic lung adenocarcinomaEGFR mutationsKRAS mutationsMetastatic tumorsEpidermal growth factor receptorLung adenocarcinomaCytological specimensGene rearrangementsMolecular testsMolecular alterationsKirsten rat sarcoma viral oncogene homolog (KRAS) mutationsALK gene rearrangement analysisAnaplastic lymphoma kinase (ALK) gene rearrangementEGFR T790M mutationRat sarcoma viral oncogene homolog mutationsCases of lungT790M mutationImportant therapeutic implicationsFine needle aspiratesGene rearrangement analysisCell block materialGrowth factor receptorRecurrent lungRecurrent adenocarcinoma
2012
Diagnostic value of K‐ras mutation analysis for pancreaticobiliary cytology specimens with indeterminate diagnosis
Cai G, Mahooti S, Lipata FM, Chhieng D, Hui P. Diagnostic value of K‐ras mutation analysis for pancreaticobiliary cytology specimens with indeterminate diagnosis. Cancer Cytopathology 2012, 120: 313-318. PMID: 22367918, DOI: 10.1002/cncy.21188.Peer-Reviewed Original Research
2009
Expression of Hepatocyte Antigen in Small Intestinal Epithelium and Adenocarcinoma
Mac MT, Chung F, Lin F, Hui P, Balzer BL, Wang HL. Expression of Hepatocyte Antigen in Small Intestinal Epithelium and Adenocarcinoma. American Journal Of Clinical Pathology 2009, 132: 80-85. PMID: 19864237, DOI: 10.1309/ajcpud0p5nqboypk.Peer-Reviewed Original ResearchConceptsSmall intestinal adenocarcinomaHep Par 1Intestinal adenocarcinomaHepatocyte antigenSmall intestinal epitheliumAntigen expressionPAR-1Hepatoid differentiationIntestinal epitheliumAntigen-negative tumorsSmall intestinal mucosaPositive cytoplasmic stainingPotential physiologic roleSmall intestinal tumorigenesisSmall intestinal enterocytesColorectal adenocarcinomaHepatocellular carcinomaAntigen immunoreactivityIntestinal mucosaIntestinal tumorigenesisDiagnostic immunomarkerPositive stainingAdenocarcinomaNonneoplastic mucosaColonic epithelium
2007
Expression of Mucins, SIMA, Villin, and CDX2 in Small-Intestinal Adenocarcinoma
Zhang MQ, Lin F, Hui P, Chen ZM, Ritter JH, Wang HL. Expression of Mucins, SIMA, Villin, and CDX2 in Small-Intestinal Adenocarcinoma. American Journal Of Clinical Pathology 2007, 128: 808-816. PMID: 17951204, DOI: 10.1309/jaf3kvgjhqcj1qf9.Peer-Reviewed Original ResearchMeSH KeywordsAdenocarcinomaAdultAgedAged, 80 and overAntigens, NeoplasmBiomarkers, TumorCDX2 Transcription FactorFemaleFluorescent Antibody Technique, IndirectHomeodomain ProteinsHumansImmunoenzyme TechniquesIntestinal NeoplasmsIntestine, SmallMaleMicrofilament ProteinsMiddle AgedMucinsNeoplasm ProteinsConceptsSmall intestinal mucin antigenSmall intestinal adenocarcinomaColorectal adenocarcinomaFocal staining patternExpression of mucinsFrequency of expressionMucin antigenFocal stainingPositive stainingDiffuse immunoreactivityAdenocarcinomaDiffuse stainingStaining patternMUC5ACMUC1MUC2Morphologic similaritiesStainingCDX2ExpressionVillinImmunoreactivityAntigenBiomarkers